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We have previously shown that the Epstein-Barr virus (EBV) immediate-early gene product, BZLF1, can
activate expression of the EBV BMLF1 immediate-early promoter in EBV-positive, but not EBV-negative, B
cells, suggesting that the BZLF1 effect may be mediated through another EBV gene product (S. Kenney, J.
Kamine, E. Holley-Guthrie, J.-C. Lin, E.-C. Mar, and J. S. Pagano, J. Virol. 63:1729-1736, 1989). Here, we
show that the EBV BRLF1 immediate-early gene product transactivates the BMLF1 promoter in either
EBV-positive or EBV-negative B cells. Deletional analysis revealed that both the BZLFl-responsive region and
the BRLFl-responsive region of the BMLF1 promoter are contained within the same 140-base-pair FokI-PvuII
fragment located 300 base pairs upstream of the mRNA start site. This FokI-PvuII fragment functions as an
enhancer element in the presence of the BRLF1 transactivator and contains the sequence CCGTGGAGA
ATGTC, which is strikingly similar to the BRLFl-responsive region of the EBV DR/DL enhancer (A.
Chevallier-Greco, H. Gruffat, E. Manet, A. Calender, and A. Sergeant, J. Virol,. 63:615-623, 1989). The effect
of BZLF1 on the BMLF1 promoter is likely to be indirect and mediated through the BRLF1 transactivator.
Epstein-Barr virus (EBV) infection of B lymphocytes is
largely latent, with only rare cells producing infectious virus.
The disruption of EBV latency in B cells is likely to involve
a complex series of interactions between virally encoded
transactivating proteins and cis-regulating functions of key
viral promoters. Three different EBV immediate-early
genes, BZLF1, BMLF1, and BRLF1, have now been shown
to encode transactivating functions (2-5, 13-16, 19, 25, 27,
28; S. Kenney, J. Kamine, E. Holley-Guthrie, and J. C. Lin,
in P. Levine, D. Ablashi, M. Nonoyama, G. Pearson, and R.
Glaser, ed., Epstein-Barr Virus and Human Disease, in
press). Of these, it appears likely that it is the BZLF1 gene
product that provides the crucial first step in the disruption
of latency, since high-level expression of the BZLF1 gene
product (but not of the BMLF1 or BRLF1 gene product) is
sufficient to disrupt latency (11, 22, 25). The BZLF1 gene
encodes a 34- to 38-kilodalton nuclear protein (20) which has
some sequence homology to the c-fos protein (8) and can
bind to the consensus Ap-1 site.
We recently reported that the BZLF1 gene product acti-
vates expression of the EBV BMLF1 immediate-early pro-
moter and showed that the stimulating effect of the BZLF1
transactivator on the BMLF1 promoter is much greater in
EBV-positive than in EBV-negative B cells (14; Kenney et
al., in press). The BMLF1 promoter contains a consensus
Ap-1 binding site approximately 100 base pairs (bp) up-
stream of the mRNA start site, and it has therefore been
suggested that the BZLF1 effect on BMLF1 promoter func-
tion may be direct, involving binding of the BZLF1 protein
to the BMLF1 promoter Ap-1 binding site (8). However, the
BMLF1 promoter sequences required for BZLF1-induced
transactivation have not been previously mapped, and the
contribution of the Ap-1 binding site in the promoter has
only been inferred. Since the BZLF1 immediate-early gene
product is a much more effective transactivator ofBMLF1 in
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EBV-infected cells, it seemed likely that its action on the
BMLF1 promoter was indirect and mediated through an-
other EBV gene product..
In this study, we have constructed a series of 5' deletion
mutants in the BMLF1 promoter (linked to the heterologous
chloramphenicol acetyltransferase [CAT] gene) and have
examined the ability of each promoter mutant to respond to
the BZLF1 transactivator. We found that the BZLF1-re-
sponsive element of the BMLF1 promoter could be localized
to a 140-bp fragment several hundred nucleotides 5' to the
cap site, suggesting that BZLF1 binding to the potential Ap-1
site is not important for BMLF1 promoter activation. We
demonstrate that, in contrast to the BZLF1 gene product,
which stimulates the BMLF1 promoter in EBV-positive
cells, the EBV immediate-early gene product, BRLF1,
transactivates the BMLF1 promoter independent of EBV
infection in transfected cells. The BRLF1-responsive region
of BMLF1 is localized within the same 140-bp fragment
responsive to the BZLF1 transactivator. This 140-bp frag-
ment transfers BRLF1 responsiveness to a heterologous
promoter and can function as an enhancer element. We
conclude that the BZLF1 effect on the BMLF1 promoter is
indirect and likely to be mediated through BRLF1.
MATERIALS AND METHODS
Cell lines. The Raji cell line is a latently infected EBV-
positive Burkitt's lymphoma B-cell line. The B95-8 cell line
is a productively infected marmoset B-cell line. The Jurkat
line is a human T-cell line, and the BJAB cell line is an
EBV-negative Burkitt's lymphoma B-cell line. The HeLa
cell line is a human cervical epithelial cell line. The lymphoid
cells lines were maintained in RPMI 1640 medium with 10%
fetal calf serum. HeLa cells were grown in Dulbecco modi-
fied Eagle medium H with 10% fetal calf serum.
DNA transfections. Plasmid DNA was purified through two
sequential cesium chloride gradients. Electroporation (26)
into lymphoid cells and HeLa cells was accomplished at
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FIG. 1. Construction of pM-CAT deletions. The parent pM-CAT
construct contains the 437-bp FokI-FokI fragment from BamHI S
(EBV nucleotides 84770 to 84333) linked to CAT. We have mapped
the BMLF1-BSLF2 RNA cap site at approximately nucleotide
84330. Previous RNA mapping has shown that the BSLF2 open
reading frame can be spliced into the BMLF1 open reading frame to
form a 50- to 60-kilodalton protein (23). A series of 5' deletion
mutants were constructed by cutting at the indicated restriction
endonuclease site, blunt ending with the T4 polymerase or Klenow
enzyme, and religating. An additional plasmid, pS-CAT (not
shown), was constructed and contains the entire EBV BamHI S
fragment linked to CAT.
1,500 V, using a Zapper electroporation unit from the
University of Wisconsin, Madison, Medical Electronics
Shop; 107 cells were transfected per condition for each CAT
assay.
EBV-CAT plasmids. EBV promoter sequences were li-
gated into the BglII site of plasmid pCAT3M (18). Plasmid
pCAT3M contains the bacterial CAT gene and a simian virus
40 (SV40) polyadenylation site but no eucaryotic promoter
element. The exact genome map locations (1) of each con-
struct are shown in Fig. 1. The pS-CAT plasmid (not shown)
contains the entire BamHI S fragment (EBV nucleotides
79537 to 84233) ligated into pCAT3M. The pM-CAT con-
struct contains the BamHI S fragment nucleotides 84770 to
84333 linked to CAT. Deletion mutants of pM-CAT were
constructed by cutting with the restriction enzymes shown,
blunt ending with T4 polymerase or the Klenow enzyme, and
then religating. We have mapped the major mRNA start site
of BMLF1 to the EBV map coordinate of approximately
84330. The pS-CAT construct (but probably not the pM-
CAT construct) contains the endogenous mRNA cap site.
Transactivator plasmids. The pEBV-ZIE plasmid, as pre-
viously described (14; Kenney et al., in press), contains the
BZLF1 gene product within the pGem-2-based vector,
phD1013 (6), under the control of the strong human cyto-
megalovirus immediate-early promoter. The pEBV-RIE
plasmid has the 2,332-bp BglII-HindIII fragment (EBV nu-
cleotides 105413 to 103080) inserted into the BamHI site of
the phD1013 vector. The resultant plasmid contains the EBV
BRLF1 gene under the control of the human cytomegalovi-
rus immediate-early promoter.
CAT assays. Cells were transfected with plasmid DNA,
and 48 h later an extract of the cells was prepared and
incubated at 37°C with 14C-labeled chloramphenicol in the
presence of acetyl coenzyme A, as previously described
(10). The percent acetylation of chloramphenicol was quan-
titated by thin-layer chromatography, followed by autoradi-
ography and scintillation counting. All CAT assays were
repeated, using smaller amounts of extract, if results were
not in the linear range (less than 70% chloramphenicol
acetylation).
RNA analysis. To quantitate CAT mRNA, cytoplasmic
RNA was prepared 24 h after transfection, as previously
described (9). A 20-bp oligonucleotide primer homologous to
the CAT gene in the region 15 to 34 bp downstream of the
ATG codon was synthesized and labeled with [_y-32P]ATP.
Labeled oligonucleotide (105 cpm) was hybridized overnight
with cytoplasmic RNA in a solution containing 80% form-
amide, 40 mM PIPES [piperazine-N,N'-bis(2-ethanesulfonic
acid)], 400 mM NaCl, and 1 mM EDTA. Primer extension
was performed at 42°C for 90 min with avian myeloblastosis
virus reverse transcriptase (21); the primer extension prod-
ucts were electrophoresed on a 6% acrylamide-7 M urea gel.
Sequence analysis. Computer searches of the EBV genome
were performed on a VAX computer, using the Wisconsin
Genetics Computer group sequence analysis software (7).
RESULTS
Constitutive activities of BMLF1 deletion mutants in dif-
ferent cell types. To study the BMLF1 promoter sequences
required for cis and trans regulation, we built a series of 5'
deletion mutants in the pM-CAT plasmid, as illustrated in
Fig. 1. The pM-CAT plasmid contains the EBV nucleotides
84770 to 84333. Five plasmids were constructed from pM-
CAT [pM-CAT(APvuII), pM-CAT(AAvaI), pM-CAT(AMstII),
pM-CAT(ABstEII), and pM-CAT(ABspl286)] which delete
progressively larger fragments of the upstream promoter
sequences.
The effects of 5' deletions on constitutive activity of the
BMLF1 promoter in several cell types are shown in Table 1.
Plasmid pCAT3M, which has no eucaryotic promoter ele-
ment, served as a negative control, and plasmid pRSV-CAT
(10), which has the strong Rous sarcoma virus promoter,
served as a positive control for transfection efficiency. In the
latently infected, EBV-positive Raji B-cell line, in which the
endogenous BMLF1 gene is not normally transcribed, nei-
ther the pS-CAT nor pM-CAT plasmids, nor any of the
deletion plasmids, produced significant CAT activity in
comparison with the negative control plasmid, pCAT3M.
Similar results were obtained in the other cell lines.
Localization of the BZLF1- and BRLFl-responsive regions.
In preliminary experiments, we found that the levels of
pS-CAT and pM-CAT activities could be greatly increased
by cotransfection with either the pEBV-ZIE (which encodes
the BZLF1 gene product) or the pEBV-RIE (which encodes
the BRLF1 gene product) constructs. To identify the
BMLF1 promoter region responsive to the BZLF1 and
BRLF1 transactivators, the pM-CAT deletion plasmids (5
,ug) were cotransfected with 5 ,ug of either the phD1013
vector, pEBV-ZIE (which encodes the BZLF1 gene prod-
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TABLE 1. Constitutive activities of BMLF1 promoter deletion plasmids in different cell types
% Acetylation in cell line (avg and range)"
Plasmid
Raji BJAB Jurkat HeLa
pS-CAT 0.7 (0.5-0.9) 0.6 (0.6-0.6) 1.2 (0.7-1.4) 1.8 (1.7-1.8)
pM-CAT 0.4 (0.3-0.5) 0.4 (0.3-0.5) 0.7 (0.6-0.7) 0.3 (0.2-0.3)
pM-CAT(APvuII) 0.4 (0.3-0.5) 0.4 (0.4-0.5) 0.7 (0.5-0.8) 0.4 (0.3-0.4)
pM-CAT(GAvaI) 0.8 (0.4-1.4) 0.5 (0.4-0.5) 1.6 (0.8-4.4) 0.5 (0.4-0.6)
pM-CAT(&MstI1) 0.5 (0.4-0.5) 0.6 (0.4-0.7) 1.3 (1.9-1.5) 0.4 (0.3-0.4)
pM-CAT(ABstEII) 0.7 (0.5-0.9) 0.8 (0.6-1.0) 2.4 (2.0-2.7) 0.4 (0.4-0.4)
pM-CAT(ABspl286) 0.2 (0.2-0.3) 0.6 (0.3-0.8) 0.4 (0.3-0.5) 0.3 (0.2-0.3)
pCAT3M 0.5 (0.4-0.6) 0.4 (0.3-0.4) 0.8 (0.7-0.8) 0.3 (0.3-0.3)
pRSV-CAT 51.0 (27.0-66.2) 18.7 (16.4-21.0) 92.3 (87.5-97.0) 98.0 (97.0-99.0)
a The values shown are derived from three experiments in Raji cells and two experiments in other cell types, using 100 R1 of cell extract.
uct), or pEBV-RIE (which encodes the BRLF1 gene prod- mRNA (14). In this study, we used the primer extension
uct). These results are shown in Tables 2 and 3. method to confirm that the BRLF1-transactivating effect
As we have previously reported (14), the BZLF1 transac- also increases CAT mRNA levels and that the mRNA start
tivator significantly increases pM-CAT activity in the EBV- site does not change in the presence of the BRLF1 transac-
positive B-cell line Raji but has little effect in EBV-negative tivator. These results are shown in Fig. 2. In the experiment
cell types. In Raji cells, BZLF1 transactivation of the shown, the pS-CAT plasmid (5 pLg) was cotransfected into
pM-CAT plasmid requires a specific region of the BMLF1 Jurkat cells with 5 ,ug of either phD1013 (lane A) or pEBV-
promoter, within the 140-bp FokI-PvuII fragment located RIE (lane B). Cytoplasmic RNA harvested 24 h after trans-
300 to 440 bp upstream of the mRNA start site (Table 2). fection was hybridized to a -y-32P-labeled primer homologous
This fragment appears to be essential for BZLF1 transacti- to the CAT gene sequences 15 to 34 bp downstream of the
vation, since all pM-CAT deletion plasmids not containing ATG codon, and primer extension was performed. The
this region of the promoter were unresponsive to the BZLF1 expected primer extension product is 170 bp, if the TATA
transactivator. box is used and no splicing occurs. Using the pS-CAT
We also examined the ability of each pM-CAT deletion plasmid, only one major 5' start site was seen, which maps to
plasmid to respond to the BRLF1 transactivator (Table 3). approximately 25 bp downstream of the TATA box.
Since preliminary experiments had shown that the BRLF1 Cotransfection with the BRLF1 transactivator clearly in-
transactivator affects pM-CAT activity in either EBV-posi- creases the level of pS-CAT mRNA and does not alter the
tive or EBV-negative cell types, the experiments shown mRNA start site.
were performed in EBV-negative cell lines to avoid the The BZLF1- and BRLF1-responsive region in the BMLF1
possibility of indirect effects induced through other EBV promoter functions as an enhancer element. Because the
gene products. As was found with the BZLF1 transactivator, BZLF1- and BRLF1-responsive element of the BMLF1
maximal response to the BRLF1 transactivator also required promoter could be localized to a specific region contained
the BMLF1 promoter sequences within the 140-bp FokI- within the 140-bp PvuII-FokI fragment, we tested the ability
PvuII fragment. Thus, the BZLF1- and BRLF1-responsive of this fragment to transfer BZLF1 and BRLF1 responsive-
elements of the BMLF1 promoter are located within the ness to the SV40 early promoter. The 140-bp fragment was
same 140-bp fragment. Since the BZLF1 effect occurs in inserted into the pAlOCAT plasmid (17) (Fig. 3) directly
EBV-positive, but not EBV-negative, B cells, the effect of upstream of the SV40 early promoter (BglII site) in either
BZLF1 on BMLF1 promoter activity may be mediated orientation or downstream of the SV40 promoter (BamHI
through BZLF1-induced activation of another EBV gene site). In addition, the 140-bp piece was divided into two
product, presumably BRLF1. smaller fragments (the 83-bp FokI-Sau3A piece and the
RNA analysis. We have previously shown that the BZLF1 57-bp Sau3A-PvuII piece), each of which was also cloned
transactivator increases the level of BMLF1-directed CAT into the BgIII site of the pAlOCAT plasmid.
TABLE 2. Effect of BZLF1 transactivator on pM-CAT deletion plasmids
Fold increase in CAT activity in cell line (avg and range)"
Plasmid
Raji Jurkat BJAB
pS-CAT 15.5 (12.6-18.3) 1.2 (1.1-1.3) NT
pM-CAT 46.8 (34.2-54.7) 1.9 (1.3-3.3) 1.4 (1.0-1.8)
pM-CAT(APvuII) 1.3 (1.2-1.3) 1.5 (0.5-3.2) 1.8 (0.9-2.6)
pM-CAT(AAvaI) 1.1 (0.4-1.4) 0.5 (0.3-0.8) 0.8 (0.6-0.9)
pM-CAT(AMstll) 1.4 (0.8-2.2) 0.6 (0.3-1.1) 1.3 (0.9-1.6)
pM-CAT(ABstEII) 1.0 (0.4-1.1) 1.1 (0.6-1.4) 1.1 (0.6-1.6)
pM-CAT(ABspl286) 1.0 (0.8-1.3) 0.7 (0.7-0.8) 0.8 (0.8-0.8)
a The numbers shown represent the average fold increase in CAT activity when each CAT plasmid was cotransfected with the pEBV-ZIE plasmid versus the
phD1013 vector. The constitutive activity produced by each CAT vector is as shown in Table 1. NT, Not tested. Ranges are those seen in four experiments in
Raji cells, three experiments in Jurkat cells (pS-CAT not used in one experiment with each cell type), and two experiments in BJAB cells.
J. VIROL.
EBV BMLF1 ENHANCER TRANSACTIVATED BY BRLF1
TABLE 3. Effect of the BRLF1 transactivator on
pM-CAT deletion plasmids
Fold increase in CAT activity in cell line (avg
Plasmid and range)a
BJAB Jurkat
pS-CAT 35.4 (32.4-38.3) 53.6 (39.4-67.7)
pM-CAT 45.6 (12.7-81.7) 63.1 (26.6-119.1)
pM-CAT(APvuII) 1.6 (1.3-1.9) 2.8 (0.7-6.6)
pM-CAT(AAvaI) 2.6 (2.1-3.3) 2.6 (1.6-3.8)
pM-CAT(AMstII) 2.4 (1.9-3.4) 1.7 (1.3-2.3)
pM-CAT(ABstEII) 1.0 (0.7-1.6) 2.1 (1.0-3.8)
pM-CAT(/Bspl286) 1.0 (0.9-1.1) 1.3 (0.9-1.9)
a The numbers shown represent the average fold increase in CAT activity
when each CAT plasmid was cotransfected with the pEBV-RIE plasmid
versus the phD1013 vector. The amount of extract used for each CAT plasmid
was adjusted to keep the total CAT activity after cotransfection with pEBV-
RIE within the linear range. Ranges are those seen in three experiments (one
experiment with each cell type did not include the pS-CAT construct).
The insertion of the intact 140-bp Sau3A-PvuII fragment
or its two subfragments into pAlOCAT had no effect on the
constitutive promoter activity produced by pAlOCAT in a
variety of cell types (BJAB, Jurkat, Raji, HeLa, and HEp-2;
data not shown). Thus, in the absence of the BRLF1 and
BZLF1 transactivating functions, the 140-bp FokI-PvuII
fragment cannot function as an enhancer element, at least in
the five cell types tested. However, when the pAlOCAT
plasmids containing the 140-bp FokI-PvuII fragment were
cotransfected into Raji cells with pEBV-ZIE, these plasmids
showed a much greater increase in CAT activity in response
to the BZLF1 transactivator than did the parent pAlOCAT
plasmid (Table 4). Whereas the activity of the parent
pAlOCAT plasmid was increased threefold in the presence
of pEBV-ZIE, the addition of the 140-bp BZLF1-responsive
region from the BMLF1 promoter to pAlOCAT resulted in
increases of 27- to 67-fold in the presence of BZLF1. Since
this increased responsiveness to the BZLF1 transactivator
occurred regardless of the orientation or position of the
140-bp fragment in pAlOCAT, this fragment functions as an
enhancer element. The 83-bp subfragment of the 140-bp
region also increased the pAlOCAT response to the BZLF1
transactivator but was not nearly as effective as the intact
140-bp fragment. The BMLF1 enhancer element was stimu-
lated by the BZLF1 transactivator in the EBV-positive Raji
cells but not in the EBV-negative Jurkat cells.
The BMLF1 enhancer fragment can also be transactivated
by the BRLF1 gene product (Table 5). BRLF-1 induced
transactivation (in contrast to the BZLF1 effect) occurred in
either EBV-negative or EBV-positive cell types. Whereas
the BRLF1 transactivator had a slight stimulating effect on
the parent plasmid, pAlOCAT (2.1- and 5.7-fold in two
separate experiments), this effect was increased greatly (up
to 134-fold) in the presence of the BMLF1 enhancer frag-
ment, regardless of the position or orientation of the frag-
ment. The intact 140-bp enhancer element also responded to
the BRLF1 transactivator in nonlymphoid cells, such as
HeLa and HEp-2 (data not shown). As with the BZLF1
transactivator, only the 83-bp subfragment, and not the
57-bp subfragment, was able to function independently as an
enhancer element, although once again the intact 140-bp
piece was the most effective enhancer.
DISCUSSION
High-level expression of the EBV immediate-early gene









FIG. 2. RNA analysis. Jurkat cells were transfected with 5 p,g of
the pS-CAT plasmid and 5 Fig of phD1013 (lane A) or with 5 ,ug of
pS-CAT and 5 ,ug of pEBV-RIE (lane B). Cytoplasmic RNA was
harvested 24 h after transfection and hybridized overnight to a
[32P]ATP-labeled primer homologous to the CAT gene in the region
15 to 34 bp downstream of the ATG codon. Primer extension (21)
was performed, and the primer extension products were run on a 6%
acrylamide-7 M urea gel. The size of the expected primer extension
product is 170 bp, assuming that the TATA box is used and no
splicing occurs (splicing is not expected with the pS-CAT construct,
since no splice acceptor sequences are included within the EBV
insert). Cotransfection of the pS-CAT plasmid with the BRLF1
transactivator (pEBV-RIE) increased the level of S-CAT mRNA
(lane B).
infection of B lymphocytes into the productive mode ofEBV
infection (11, 22, 25). The BZLF1 gene encodes a regulatory
protein which shares homology with the c-fos gene product
(8) and has been shown to enhance the expression of several
different EBV early promoters (2-4, 13, 14), but little is
known about the promoter sequences required for BZLF1
response. In this article, we demonstrate that the BZLF1-
responsive sequence in the BMLF1 immediate-early pro-
moter is contained within a 140-bp enhancer element. We
show that this enhancer element is also transactivated by the
EBV BRLF1 immediate-early gene product. We conclude
that BZLF1 transactivation of the BMLF1 promoter is likely
to be indirect and mediated through the BRLF1 transactiva-
tor, since a strong BZLF1 effect is seen in EBV-positive but
not EBV-negative cell types.
In many respects, our findings concerning the BMLF1
immediate-early promoter are similar to the studies on the
EBV DR/DL (duplicated right and left) promoter recently
published by Chevallier-Greco et al. (2, 3). These investiga-
tors concluded that BZLFl-induced transactivation of the
DR/DL promoter in EBV-positive cells is mediated through
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TABLE 5. Effect of the BRLF1 transactivator on pAlOCAT-Z*
plasmids in Jurkat cells
Fold increase in CAT activity"
Plasmid




pAlOCAT-Z*(83 bp) 16.5 20.7
pAlOCAT-Z*(57 bp) 4.9 3.1
Fok-l a The numbers represent the fold increase in CAT activity produced by
TATA cotransfection with the pEBV-RIE plasmid versus the pHD1013 vector.
84,333
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pAIOCAT-Z-(sense) Fok- PvuII












FIG. 3. Construction of pAlOCAT-Z* plasmids. The intact 140-
bp BZLFl-responsive region from the BMLF1 promoter (here
referred to as the Z* region) was inserted into the pAlOCAT vector
(which contains the SV40 early promoter, but not enhancer, linked
to CAT) in either orientation at the BgII site, as well as downstream
at the BamHI site. In addition, the 83-bp FokI-Sau3A fragment and
the 57-bp Sau3A-FokI fragment were inserted into the BglII site of
pAlOCAT.
BRLF1-responsive region of the DR/DL promoter can func-
tion as an enhancer element. In addition, the 28-bp sequence
CTGTGCCTTGTCCCGTGGACAATGTCCC found in the
DR/DL promoter was sufficient to confer BRLF1 respon-
siveness in a heterologous promoter.
Strikingly, the 83-bp subfragment of the BMLF1 en-
hancer, which is also sufficient to confer BRLF1 responsive-
ness to a heterologous promoter (albeit with reduced effi-
ciency compared with the intact 140-bp enhancer), contains
the sequence CCGTGGAGAATGTC, which has a 13- to
14-bp identity to the DR/DL BRLF1 response element,
CCGTGGACAATGTC. In addition, imperfect copies of the
sequence CTGGGC are repeated multiple times within the
140-bp BMLF1 enhancer fragment. When we searched the
entire EBV genome in both orientations for the DRIDL
TABLE 4. Effect of BZLF1 transactivator on
pAlOCAT-Z* plasmids
Fold increase in CAT






pAlOCAT-Z*(83 bp) 9.6 3.6
pAlOCAT-Z*(57 bp) 2.3 1.7
" The numbers shown are the fold increase in CAT activity seen when each
CAT plasmid was cotransfected with the pEBV-ZIE plasmid versus the
pHD1013 plasmid.
promoter sequence CCGTGGACAATGTC (allowing 1-bp
mismatch), this sequence was found only twice: in the
BHRF1 promoter, which contains the left-hand copy of the
DR/DL promoter and responds to the BRLF1 transactivator
(13), and in the BMLF1 enhancer. Therefore, the finding that
three different BRLF1-responsive enhancers each contain
the sequence CCGTGGA(C/G)AATGTC strongly suggests
that this sequence plays a crucial role in conferring BRLF1
responsiveness. At this point, it is not known whether the
BRLF1 protein can bind to this sequence directly or acts by
stimulating the binding of cellular transcription factors.
The potential Ap-1 site, located within the Bsp 1286-
BstEII fragment, was not demonstrated to be important for
trans-acting regulation of the BMLF1 promoter in this study.
Conceivably, the low-level transactivation induced by the
BZLF1 gene product in EBV-negative cells might involve
binding to this Ap-1 site. We have found that simultaneous
cotransfection of the BMLF1 promoter with both the
BRLF1 and BZLF1 transactivators into EBV-negative cells
produces no greater activation than that seen with the
BRLF1 transactivator alone, provided that the BRLF1
transactivator is driven by a strong heterologous promoter.
Therefore, at this point we do not believe that the BZLF1
gene product plays an important role in regulating the
BMLF1 promoter, other than indirectly through its pre-
sumed effect on BRLF1 promoter activity. On the other
hand, we have previously shown that the promoter of the
EBV BMRF1 gene, which encodes the early antigen diffuse
protein, can be transactivated by the BZLF1 gene product
equally well in EBV-negative and EBV-positive cell types
(14). This result suggests that the BZLF1 effect on the EBV
BMRF1 promoter is direct and not mediated through other
EBV gene products.
The demonstration of an enhancer element within BMLF1
may help to explain the efficiency with which the defective
P3HRI (het) virions disrupt viral latency. We have previ-
ously shown that the endogenous promoter of the BZLF1
gene is extremely weak, although its activity can be in-
creased somewhat with 12-O-tetradecanoylphorbol-13-ace-
tate (16). We have also shown that the BZLF1 promoter is
not significantly transactivated by its own gene product (14).
However, in the defective P3HRI (het) virions, the normal
genomic locations of BMLF1 and BZLF1 have been altered
such that the BMLF1 enhancer region is now located within
5 kilobases downstream of the BZLF1-encoding region (22).
This juxtaposition of the BMLF1 enhancer with the BZLF1
gene presumably allows the BZLF1 gene product to enhance
its own expression (through BRLF1-induced transactivation
of the adjacent BMLF1 enhancer region), an event which
probably cannot occur in the intact EBV genome.
Two EBV enhancers have now been identified which
respond to the BRLF1 immediate-early transactivator. One
J. VIROL.
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of these, the DR/DL enhancer, is present in two copies in
most strains of EBV. The DR/DL enhancer can cis activate
expression of the cytoplasmic early antigen (BHRF1) gene
(13) and was recently shown to play an essential role in the
EBV lytic origin of replication (12). The other enhancer
function, BMLF1, could potentially cis activate expression
of both the BMLF1 gene, which encodes a transactivating
function, and the early antigen diffuse gene, which is located
only 5 kilobases upstream of the BMLF1 enhancer. The
crucial first step in BZLF1-induced disruption of viral la-
tency is likely to involve activation of BRLF1 expression,
which then leads to activation of the BRLF1-responsive
enhancers. Regulation of BRLF1 expression by BZLF1 will
be a key area for future investigation.
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